FDA Adverse Event Injury Summary report: N

ASR UNI FEMORAL IMPL SIZE 43

MDR report key: 2071367 · Received April 13, 2011

Report

Report Number
1818910-2011-06078
Event Type
Injury
Date Received
April 13, 2011
Date of Event
March 14, 2011
Report Date
March 14, 2011
Manufacturer
DEPUY INTERNATIONAL, LTD.
Product Code
KWA
PMA / PMN Number
K040627
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

ADDITIONAL INFORMATION: DESCRIBE EVENT OR PROBLEM, PATIENT CODE, REPORT SOURCE. DEPUY STILL CONSIDERS THE INVESTIGATION CLOSED. SHOULD ADDITIONAL INFORMATION BE RECEIVED THE INVESTIGATION WILL BE REOPENED.

Additional Manufacturer Narrative · 1

UPDATE: (B)(6) 2012 - INFORMATION FROM OUTSIDE COUNSEL PROVIDES DOI OF (B)(6) 2006. DEPUY STILL CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED.

Additional Manufacturer Narrative · 1

THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. (B)(4). DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED.

Additional Manufacturer Narrative · 1

THIS COMPLAINT IS STILL UNDER INVESTIGATION. DEPUY WILL NOTIFY THE FDA OF THE RESULTS OF THIS INVESTIGATION ONCE IT HAS BEEN COMPLETED.

Description of Event or Problem · 1

UPDATE: CLINICAL REPORT NOTES THAT THE PATIENT ALSO HAD PAIN/STIFFNESS.

Description of Event or Problem · 1

PT REVISED TO ADDRESS METALLOSIS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ASR UNI FEMORAL IMPL SIZE 43 87KWA KWA DEPUY INTERNATIONAL, LTD. NA 2171089

Patients

Seq Age Sex Outcome Treatment
1 59 YR Required Intervention